Neurotech International Ltd has released a press release.
Phase I/II PANDAS/PANS Clinical Trial Meets Primary Endpoint
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurotech International Ltd. on 6ix
In the deck
Earlier from Neurotech International
- Completion of Patient Recruitment in NTIRTT1 Clinical Trial
- Last Patient Completes Treatment in NTIPANS1 Clinical Trial
- Appendix 4E & Annual Report
- First Patient Treated in Rett Syndrome Clinical Trial
- NTI Receives HREC Approval for Rett Syndrome Clinical Trial
Later from Neurotech International
- Neurotech Receives $3.17 Million R&D Tax Incentive Refund
- HREC Approval to Extend Phase II/III ASD Trial to Adults
- Phase II/III Autism Clinical Trial Completes Recruitment
- NTI Receives HREC Approval for Cerebral Palsy Trial
- Neurotech Receives Additional HREC Approval in Autism
Follow Neurotech International into a list and get an email when it puts out news.
Follow Neurotech International